Unique ID issued by UMIN | UMIN000017890 |
---|---|
Receipt number | R000020728 |
Scientific Title | Enhancement of healing for extruded injured meniscus by transplantation of synovial stem cells after meniscus surgery. |
Date of disclosure of the study information | 2015/06/12 |
Last modified on | 2016/12/11 21:14:23 |
Enhancement of healing for extruded injured meniscus by transplantation of synovial stem cells after meniscus surgery.
Enhancement of healing for extruded injured meniscus by transplantation of synovial stem cells after meniscus surgery.
Enhancement of healing for extruded injured meniscus by transplantation of synovial stem cells after meniscus surgery.
Enhancement of healing for extruded injured meniscus by transplantation of synovial stem cells after meniscus surgery.
Japan |
Knee meniscal tear
Orthopedics |
Others
NO
To improve the clinical results for the extruded injured meniscus, autologous synovial mesenchymalstem cells (MSCs) are transplanted to the knee following meniscus repair with centralization technique. The main purpose of this study is to evaluate the safety of synovial MSCs.
Safety
Adverse event data, including type, frequency, severity and duration
1) Safety of the autologous synovial mesenchymal stem cells
2) Subjective score by KOOS and NRS, Observation of knee, Knee functional evaluation by McMurry test and pivot shift test, Lysholm score
3) MRI examination
4) Knee X-ray examination
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver | Other |
Arthroscopic transplantation of synovial MSCs after meniscus repair with centralization technique
20 | years-old | <= |
Not applicable |
Male and Female
1) Extruded meniscus injury with radial, horizontal, degenerative tear etc. to which meniscal resection is generally indicated
2) Patients with clinical symptoms such as knee joint unstability, limitation in range of motion, hydrarthrosis and pain
3) Patients suitable for surgery
4) Patients to whom meniscal repair is technically possible
5) Patients older than 20 years on the acquisition date of informed consent before clinical study
6) Patients who gave a written informed consent
1) Patients who didn't give a written informed consent
2) Patients with active infection
3) Patients positive for HIV (HIV-1, 2 Ag, Ab), HBV (HBs Ag), HCV (HCV Ab), or HTLV-1 (HTLV-1 Ab)
4) Patients with active malignant tumors
5) Patients sensitive to antibiotic
6) Pregnant or breast-feeding women
7) Patients with diabetes
8) Patients in bad general physical condition
9) When doctors decide as not appropriate to participate in the clinical study
10
1st name | |
Middle name | |
Last name | Ichiro Sekiya |
Tokyo Medical and Dental University
Center for Stem Cell and Regenerative Medicine
1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
03-5803-4977
sekiya.arm@tmd.ac.jp
1st name | |
Middle name | |
Last name | Office administrator |
Medical Hospital of Tokyo Medical and Dental University
Clinical Research Center
1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan
03-5803-5612
tiken.crc@tmd.ac.jp
Medical Hospital of Tokyo Medical and Dental University
Japan Agency for Medical Research and Development
Other
NO
2015 | Year | 06 | Month | 12 | Day |
Unpublished
Completed
2015 | Year | 04 | Month | 27 | Day |
2015 | Year | 07 | Month | 08 | Day |
2016 | Year | 05 | Month | 31 | Day |
2015 | Year | 06 | Month | 12 | Day |
2016 | Year | 12 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020728